Repression of HPV E6-activated RSV promoter activity by anti-cancer agents

Cited 5 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorYun Hee Kang-
dc.contributor.authorMan Jong Kang-
dc.contributor.authorS G Paik-
dc.contributor.authorSue Nie Park-
dc.contributor.authorDo Young Yoon-
dc.date.accessioned2017-04-19T08:59:48Z-
dc.date.available2017-04-19T08:59:48Z-
dc.date.issued2003-
dc.identifier.issn0166-3542-
dc.identifier.uri10.1016/S0166-3542(02)00190-0ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/6098-
dc.description.abstractHuman papillomavirus E6 forms a complex with p53 tumor suppressor and E6-associated protein, leading to the degradation of p53 via the ubiquitination pathway, resulting in the oncogenesis of cervical carcinomas. Several viral and cellular gene promoters were shown to be transactivated by E6 oncogene. In this study, to understand the role of transcription activity of E6 related to cervical carcinogenesis, the effect of cervical cancer drugs on E6 induced transcription activity has been elucidated. Several viral promoter (RSV, CMV, SV40, and HIV) - luciferase reporter gene constructs, and eukaryotic E6 expression vector were prepared as an E6 transcription analysis system and an exogenous E6 protein source, respectively. It was shown that the promoters of RSV, SV40, and HIV, but not CMV, were transactivated by HPV 16 E6 in cervical cancer cell line. Several known cervical cancer drugs were investigated for their effects on transcription activity of E6 in SiHa stably transfected with E6-responsive promoters. Cervical cancer drugs consistently reduced luciferase activity, in transfectants with RSV-luc (SiHa/pRSV-luc, KCTC 0427BP) E6 mRNA also. Thus, in this study, we have demonstrated that the promoters of RSV, HIV, and SV40 were transactivated by E6 in cervical cancer cells. Three cervical cancer drugs downregulated RSV-luc transcription and E6 expression by a p53 independent pathway. RSV-luc promoter analysis system could be useful for understanding the role of transcription activity of E6 related to cervical cancer and also for screening drugs against cervical cancers caused by HPV infection.-
dc.publisherElsevier-
dc.titleRepression of HPV E6-activated RSV promoter activity by anti-cancer agents-
dc.title.alternativeRepression of HPV E6-activated RSV promoter activity by anti-cancer agents-
dc.typeArticle-
dc.citation.titleAntiviral Research-
dc.citation.number1-
dc.citation.endPage71-
dc.citation.startPage65-
dc.citation.volume58-
dc.contributor.affiliatedAuthorYun Hee Kang-
dc.contributor.affiliatedAuthorMan Jong Kang-
dc.contributor.affiliatedAuthorSue Nie Park-
dc.contributor.affiliatedAuthorDo Young Yoon-
dc.contributor.alternativeName강윤희-
dc.contributor.alternativeName강만종-
dc.contributor.alternativeName백상기-
dc.contributor.alternativeName박순희-
dc.contributor.alternativeName윤도영-
dc.identifier.bibliographicCitationAntiviral Research, vol. 58, no. 1, pp. 65-71-
dc.identifier.doi10.1016/S0166-3542(02)00190-0-
dc.subject.keywordcervical cancer drugs-
dc.subject.keywordHPV 16 E6-
dc.subject.keywordtranscription activity-
dc.subject.keywordviral promoter-
dc.subject.localcervical cancer drugs-
dc.subject.localHPV 16 E6-
dc.subject.localHPV16 E6-
dc.subject.localtranscription activity-
dc.subject.localviral promoter-
dc.description.journalClassY-
Appears in Collections:
1. Journal Articles > Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.